

FSG Invests in Fida Biosystems to Accelerate Growth in Biophysical Analysis

Lund, Sweden – December 16, 2025 – Fåhraeus Startup & Growth Fund II (FSG) today announces its investment in **Fida Biosystems**, a Danish life science tools company developing advanced platforms for biophysical analysis. The investment is part of a **€5 million extension of Fida Biosystems' Series A financing**, completed alongside existing investor **EIFO**, the Export and Investment Fund of Denmark.

The funding will further accelerate Fida Biosystems' growth and support continued international expansion and scaling, while preparing the company for a future Series B financing round.

Fida Biosystems has developed a biophysical analysis platform that enables **faster and more accurate characterisation of molecules and nanoparticles**, ultimately supporting the development of new medicines. Over the past year, the company has **doubled its revenue**, and with **more than 100 instruments sold** it is seeing increased adoption across industry and leading research institutions.

“With FSG’s focus on Scandinavian companies at the cross-section of Technology and Life Science we are proud to invest in FidaBio and its unique first principle technology for biophysical analysis for the Pharma and Biotech industry. We look forward to working closely with the Fidabio team and EIFO as lead investors in the next phase of the company’s growth,” said **Linus Wiebe, General Partner and Managing Director at FSG**.

“As we close a year marked by more than double growth, we are pleased to complete a new round led by FSG, with continued support from EIFO and our other investors. With our amended team, we are confident that we are in the best possible position to continue supporting researchers in developing faster and better drugs - and to further accelerate the company’s growth,” said **Brian Sørensen, CEO of Fida Biosystems**.

“Fida’s technology aligns perfectly with EIFO’s focus on innovation that drives growth. We have strong confidence in the team and are pleased to support the company’s further expansion and scaling, reinforcing Denmark’s role in life science,” said **Tonni Bülow-Nielsen, Partner at EIFO’s team for Direct Life Science Investment**.

About Fida Biosystems

Fida Biosystems develops advanced analytical platforms based on its proprietary **Flow Induced Dispersion Analysis (FIDA)** technology. This innovation enables rapid and precise analysis of biomolecules and nanoparticles directly in complex biological samples, helping biotech and pharmaceutical companies better understand molecular behavior and accelerate drug development.

About Fåhraeus Startup & Growth (FSG)

Fåhraeus Startup & Growth FSG Fund II (FSG) is a leading Nordic venture capital fund specializing in supporting high-impact startups and growth-stage companies in technology and life sciences. FSG combines strategic investments with deep industry expertise to empower transformative innovations. **FSG Fund II is supported by the European Investment Fund (EIF)**.

For media inquiries

Linus Wiebe, GP and Managing Director, (FSG Fund II) | linus.wiebe@fsgfond.com

Brian Sørensen, CEO, Fida Biosystems | brian@fidabio.com